{"transactions":[{"id":742185,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":39423,"kind":"person","name":"DEPTULA-HICKS DARLENE M","position":1,"cik":"0001089409","reported_name":"DEPTULA-HICKS DARLENE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-11T20:18:19.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":9756,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Audit Committee of the Board of Directors of the Issuer through the applicable vesting date."}],"balance_after":9756,"derivative":{"exercise_price":1.72,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":9756},"source":{"system":"sec-edgar","filing":"0001193125-26-267587","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1089409/000119312526267587/ownership.xml","form_type":"4"}},{"id":742184,"issuer":{"id":6839,"kind":"organization","name":"Aldeyra Therapeutics, Inc."},"owners":[{"id":39423,"kind":"person","name":"DEPTULA-HICKS DARLENE M","position":1,"cik":"0001089409","reported_name":"DEPTULA-HICKS DARLENE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-11T20:18:19.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":84557,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option is exercisable in equal annual installments over three years of continuous service to the Issuer after June 9, 2026."}],"balance_after":84557,"derivative":{"exercise_price":1.72,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":84557},"source":{"system":"sec-edgar","filing":"0001193125-26-267587","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1089409/000119312526267587/ownership.xml","form_type":"4"}},{"id":1961561,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":39423,"kind":"person","name":"DEPTULA-HICKS DARLENE M","position":1,"cik":"0001089409","reported_name":"DEPTULA-HICKS DARLENE M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2023-03-09T14:18:39.000Z","date":"2023-03-08","kind":"disposition_to_issuer","acquired":false,"shares":24902,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms was accelerated and became fully vested and exercisable immediately prior to, and contingent upon, the Effective Time (except in the case of the EMI Options (as defined in the Merger Agreement) granted pursuant to Rule 9.8 of the F-star Therapeutics, Inc. 2019 Equity Incentive Plan, which were accelerated and became fully vested and exercisable as of three business days prior to the Initial Expiration Date (as defined in the Merger Agreement))."},{"field":"kind","element":"transactionCoding","label":"F3","text":"As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that was less than the Offer Price (each, an \"In the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Company Shares (as defined in the Merger Agreement) subject to such fully vested option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price over (B) the exercise price payable per Company Share under such option."},{"field":"kind","element":"transactionCoding","label":"F4","text":"(Continued from footnote 3) As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an \"Out of the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. Any EMI Option that remained outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time and treated as either an In the Money Option or an Out of the Money Option."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms was accelerated and became fully vested and exercisable immediately prior to, and contingent upon, the Effective Time (except in the case of the EMI Options (as defined in the Merger Agreement) granted pursuant to Rule 9.8 of the F-star Therapeutics, Inc. 2019 Equity Incentive Plan, which were accelerated and became fully vested and exercisable as of three business days prior to the Initial Expiration Date (as defined in the Merger Agreement))."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that was less than the Offer Price (each, an \"In the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Company Shares (as defined in the Merger Agreement) subject to such fully vested option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price over (B) the exercise price payable per Company Share under such option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued from footnote 3) As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an \"Out of the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. Any EMI Option that remained outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time and treated as either an In the Money Option or an Out of the Money Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms was accelerated and became fully vested and exercisable immediately prior to, and contingent upon, the Effective Time (except in the case of the EMI Options (as defined in the Merger Agreement) granted pursuant to Rule 9.8 of the F-star Therapeutics, Inc. 2019 Equity Incentive Plan, which were accelerated and became fully vested and exercisable as of three business days prior to the Initial Expiration Date (as defined in the Merger Agreement))."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that was less than the Offer Price (each, an \"In the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Company Shares (as defined in the Merger Agreement) subject to such fully vested option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price over (B) the exercise price payable per Company Share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued from footnote 3) As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an \"Out of the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. Any EMI Option that remained outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time and treated as either an In the Money Option or an Out of the Money Option."}],"balance_after":0,"derivative":{"exercise_price":3.55,"expiration_date":"2022-03-31","underlying":"Common Stock","underlying_shares":24902},"source":{"system":"sec-edgar","filing":"0000899243-23-007665","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1089409/000089924323007665/doc4.xml","form_type":"4"}},{"id":1961560,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":39423,"kind":"person","name":"DEPTULA-HICKS DARLENE M","position":1,"cik":"0001089409","reported_name":"DEPTULA-HICKS DARLENE M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2023-03-09T14:18:39.000Z","date":"2023-03-08","kind":"disposition_to_issuer","acquired":false,"shares":59823,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms was accelerated and became fully vested and exercisable immediately prior to, and contingent upon, the Effective Time (except in the case of the EMI Options (as defined in the Merger Agreement) granted pursuant to Rule 9.8 of the F-star Therapeutics, Inc. 2019 Equity Incentive Plan, which were accelerated and became fully vested and exercisable as of three business days prior to the Initial Expiration Date (as defined in the Merger Agreement))."},{"field":"kind","element":"transactionCoding","label":"F3","text":"As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that was less than the Offer Price (each, an \"In the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Company Shares (as defined in the Merger Agreement) subject to such fully vested option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price over (B) the exercise price payable per Company Share under such option."},{"field":"kind","element":"transactionCoding","label":"F4","text":"(Continued from footnote 3) As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an \"Out of the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. Any EMI Option that remained outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time and treated as either an In the Money Option or an Out of the Money Option."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms was accelerated and became fully vested and exercisable immediately prior to, and contingent upon, the Effective Time (except in the case of the EMI Options (as defined in the Merger Agreement) granted pursuant to Rule 9.8 of the F-star Therapeutics, Inc. 2019 Equity Incentive Plan, which were accelerated and became fully vested and exercisable as of three business days prior to the Initial Expiration Date (as defined in the Merger Agreement))."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that was less than the Offer Price (each, an \"In the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Company Shares (as defined in the Merger Agreement) subject to such fully vested option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price over (B) the exercise price payable per Company Share under such option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued from footnote 3) As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an \"Out of the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. Any EMI Option that remained outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time and treated as either an In the Money Option or an Out of the Money Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms was accelerated and became fully vested and exercisable immediately prior to, and contingent upon, the Effective Time (except in the case of the EMI Options (as defined in the Merger Agreement) granted pursuant to Rule 9.8 of the F-star Therapeutics, Inc. 2019 Equity Incentive Plan, which were accelerated and became fully vested and exercisable as of three business days prior to the Initial Expiration Date (as defined in the Merger Agreement))."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that was less than the Offer Price (each, an \"In the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Company Shares (as defined in the Merger Agreement) subject to such fully vested option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price over (B) the exercise price payable per Company Share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued from footnote 3) As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an \"Out of the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. Any EMI Option that remained outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time and treated as either an In the Money Option or an Out of the Money Option."}],"balance_after":0,"derivative":{"exercise_price":4.77,"expiration_date":"2032-01-09","underlying":"Common Stock","underlying_shares":59823},"source":{"system":"sec-edgar","filing":"0000899243-23-007665","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1089409/000089924323007665/doc4.xml","form_type":"4"}},{"id":1961559,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":39423,"kind":"person","name":"DEPTULA-HICKS DARLENE M","position":1,"cik":"0001089409","reported_name":"DEPTULA-HICKS DARLENE M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2023-03-09T14:18:39.000Z","date":"2023-03-08","kind":"disposition_to_issuer","acquired":false,"shares":25894,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms was accelerated and became fully vested and exercisable immediately prior to, and contingent upon, the Effective Time (except in the case of the EMI Options (as defined in the Merger Agreement) granted pursuant to Rule 9.8 of the F-star Therapeutics, Inc. 2019 Equity Incentive Plan, which were accelerated and became fully vested and exercisable as of three business days prior to the Initial Expiration Date (as defined in the Merger Agreement))."},{"field":"kind","element":"transactionCoding","label":"F3","text":"As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that was less than the Offer Price (each, an \"In the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Company Shares (as defined in the Merger Agreement) subject to such fully vested option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price over (B) the exercise price payable per Company Share under such option."},{"field":"kind","element":"transactionCoding","label":"F4","text":"(Continued from footnote 3) As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an \"Out of the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. Any EMI Option that remained outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time and treated as either an In the Money Option or an Out of the Money Option."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms was accelerated and became fully vested and exercisable immediately prior to, and contingent upon, the Effective Time (except in the case of the EMI Options (as defined in the Merger Agreement) granted pursuant to Rule 9.8 of the F-star Therapeutics, Inc. 2019 Equity Incentive Plan, which were accelerated and became fully vested and exercisable as of three business days prior to the Initial Expiration Date (as defined in the Merger Agreement))."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that was less than the Offer Price (each, an \"In the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Company Shares (as defined in the Merger Agreement) subject to such fully vested option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price over (B) the exercise price payable per Company Share under such option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued from footnote 3) As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an \"Out of the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. Any EMI Option that remained outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time and treated as either an In the Money Option or an Out of the Money Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms was accelerated and became fully vested and exercisable immediately prior to, and contingent upon, the Effective Time (except in the case of the EMI Options (as defined in the Merger Agreement) granted pursuant to Rule 9.8 of the F-star Therapeutics, Inc. 2019 Equity Incentive Plan, which were accelerated and became fully vested and exercisable as of three business days prior to the Initial Expiration Date (as defined in the Merger Agreement))."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that was less than the Offer Price (each, an \"In the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Company Shares (as defined in the Merger Agreement) subject to such fully vested option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price over (B) the exercise price payable per Company Share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued from footnote 3) As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an \"Out of the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. Any EMI Option that remained outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time and treated as either an In the Money Option or an Out of the Money Option."}],"balance_after":0,"derivative":{"exercise_price":7.34,"expiration_date":"2031-03-09","underlying":"Common Stock","underlying_shares":25894},"source":{"system":"sec-edgar","filing":"0000899243-23-007665","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1089409/000089924323007665/doc4.xml","form_type":"4"}},{"id":1961558,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":39423,"kind":"person","name":"DEPTULA-HICKS DARLENE M","position":1,"cik":"0001089409","reported_name":"DEPTULA-HICKS DARLENE M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2023-03-09T14:18:39.000Z","date":"2023-03-08","kind":"disposition_to_issuer","acquired":false,"shares":28426,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms was accelerated and became fully vested and exercisable immediately prior to, and contingent upon, the Effective Time (except in the case of the EMI Options (as defined in the Merger Agreement) granted pursuant to Rule 9.8 of the F-star Therapeutics, Inc. 2019 Equity Incentive Plan, which were accelerated and became fully vested and exercisable as of three business days prior to the Initial Expiration Date (as defined in the Merger Agreement))."},{"field":"kind","element":"transactionCoding","label":"F3","text":"As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that was less than the Offer Price (each, an \"In the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Company Shares (as defined in the Merger Agreement) subject to such fully vested option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price over (B) the exercise price payable per Company Share under such option."},{"field":"kind","element":"transactionCoding","label":"F4","text":"(Continued from footnote 3) As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an \"Out of the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. Any EMI Option that remained outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time and treated as either an In the Money Option or an Out of the Money Option."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms was accelerated and became fully vested and exercisable immediately prior to, and contingent upon, the Effective Time (except in the case of the EMI Options (as defined in the Merger Agreement) granted pursuant to Rule 9.8 of the F-star Therapeutics, Inc. 2019 Equity Incentive Plan, which were accelerated and became fully vested and exercisable as of three business days prior to the Initial Expiration Date (as defined in the Merger Agreement))."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that was less than the Offer Price (each, an \"In the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Company Shares (as defined in the Merger Agreement) subject to such fully vested option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price over (B) the exercise price payable per Company Share under such option."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued from footnote 3) As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an \"Out of the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. Any EMI Option that remained outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time and treated as either an In the Money Option or an Out of the Money Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms was accelerated and became fully vested and exercisable immediately prior to, and contingent upon, the Effective Time (except in the case of the EMI Options (as defined in the Merger Agreement) granted pursuant to Rule 9.8 of the F-star Therapeutics, Inc. 2019 Equity Incentive Plan, which were accelerated and became fully vested and exercisable as of three business days prior to the Initial Expiration Date (as defined in the Merger Agreement))."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that was less than the Offer Price (each, an \"In the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Company Shares (as defined in the Merger Agreement) subject to such fully vested option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price over (B) the exercise price payable per Company Share under such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued from footnote 3) As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an \"Out of the Money Option\") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. Any EMI Option that remained outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time and treated as either an In the Money Option or an Out of the Money Option."}],"balance_after":0,"derivative":{"exercise_price":16.62,"expiration_date":"2029-05-01","underlying":"Common Stock","underlying_shares":28426},"source":{"system":"sec-edgar","filing":"0000899243-23-007665","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1089409/000089924323007665/doc4.xml","form_type":"4"}},{"id":1961557,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":39423,"kind":"person","name":"DEPTULA-HICKS DARLENE M","position":1,"cik":"0001089409","reported_name":"DEPTULA-HICKS DARLENE M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-03-09T14:18:39.000Z","date":"2023-03-08","kind":"disposition_to_issuer","acquired":false,"shares":25539,"price":7.12,"value":181837.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated June 22, 2022 (the \"Merger Agreement\"), by and among the Issuer, Sino Biopharmaceutical Limited, Fennec Acquisition Incorporated (\"Parent\"), and invoX Pharma Limited (\"Purchaser\"), including the completion on March 8, 2023 of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $7.12 per share in cash, without interest, less any required withholding taxes (the \"Offer Price\"), and the consummation of the merger (the \"Merger\") between the Issuer and Purchaser on March 8, 2023. Pursuant to the Merger Agreement, as of the"},{"field":"kind","element":"transactionCoding","label":"F5","text":"Each Company RSU (as defined in the Merger Agreement) that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive an amount in cash equal to the product of (a) the total number of Shares (as defined the Merger Agreement) issuable in settlement of such Company RSU immediately prior to the Effective Time without regard to vesting multiplied by (b) the Merger Consideration (as defined in the Merger Agreement)."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated June 22, 2022 (the \"Merger Agreement\"), by and among the Issuer, Sino Biopharmaceutical Limited, Fennec Acquisition Incorporated (\"Parent\"), and invoX Pharma Limited (\"Purchaser\"), including the completion on March 8, 2023 of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $7.12 per share in cash, without interest, less any required withholding taxes (the \"Offer Price\"), and the consummation of the merger (the \"Merger\") between the Issuer and Purchaser on March 8, 2023. Pursuant to the Merger Agreement, as of the"},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each Company RSU (as defined in the Merger Agreement) that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive an amount in cash equal to the product of (a) the total number of Shares (as defined the Merger Agreement) issuable in settlement of such Company RSU immediately prior to the Effective Time without regard to vesting multiplied by (b) the Merger Consideration (as defined in the Merger Agreement)."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-23-007665","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1089409/000089924323007665/doc4.xml","form_type":"4"}},{"id":1961556,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":39423,"kind":"person","name":"DEPTULA-HICKS DARLENE M","position":1,"cik":"0001089409","reported_name":"DEPTULA-HICKS DARLENE M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-03-09T14:18:39.000Z","date":"2023-03-08","kind":"other","acquired":false,"shares":30898,"price":7.12,"value":219993.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated June 22, 2022 (the \"Merger Agreement\"), by and among the Issuer, Sino Biopharmaceutical Limited, Fennec Acquisition Incorporated (\"Parent\"), and invoX Pharma Limited (\"Purchaser\"), including the completion on March 8, 2023 of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $7.12 per share in cash, without interest, less any required withholding taxes (the \"Offer Price\"), and the consummation of the merger (the \"Merger\") between the Issuer and Purchaser on March 8, 2023. Pursuant to the Merger Agreement, as of the"},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated June 22, 2022 (the \"Merger Agreement\"), by and among the Issuer, Sino Biopharmaceutical Limited, Fennec Acquisition Incorporated (\"Parent\"), and invoX Pharma Limited (\"Purchaser\"), including the completion on March 8, 2023 of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $7.12 per share in cash, without interest, less any required withholding taxes (the \"Offer Price\"), and the consummation of the merger (the \"Merger\") between the Issuer and Purchaser on March 8, 2023. Pursuant to the Merger Agreement, as of the"}],"balance_after":25539,"source":{"system":"sec-edgar","filing":"0000899243-23-007665","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1089409/000089924323007665/doc4.xml","form_type":"4"}},{"id":2309235,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":39423,"kind":"person","name":"DEPTULA-HICKS DARLENE M","position":1,"cik":"0001089409","reported_name":"DEPTULA-HICKS DARLENE M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Treasurer and CFO"}}],"security":"Stock Option (right to buy)","published_at":"2022-04-04T20:06:10.000Z","date":"2022-03-31","kind":"grant","acquired":true,"shares":24902,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These options were granted under the Issuer's 2019 Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Twenty five percent (25%) of the total number of shares under the award shall vest on the first anniversary of the Vesting Commencement Date, March 31, 2022, and thereafter in 36 equal monthly installments such that the stock option shall be fully-vested on the fourth anniversary of the Vesting Commencement Date."}],"balance_after":24902,"derivative":{"exercise_price":3.55,"expiration_date":"2032-03-31","underlying":"Common Stock","underlying_shares":24902},"source":{"system":"sec-edgar","filing":"0001209191-22-022308","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1089409/000120919122022308/doc4.xml","form_type":"4"}},{"id":2438194,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":39423,"kind":"person","name":"DEPTULA-HICKS DARLENE M","position":1,"cik":"0001089409","reported_name":"DEPTULA-HICKS DARLENE M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Treasurer and CFO"}}],"security":"Stock Option (right to buy)","published_at":"2022-01-11T22:31:34.000Z","date":"2022-01-09","kind":"grant","acquired":true,"shares":59823,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These options were granted under the Issuer's 2019 Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Twenty five percent (25%) of the total number of shares under the award shall vest on the first anniversary of the Vesting Commencement Date, January 9, 2022, and thereafter in 36 equal monthly installments such that the stock option shall be fully-vested on the fourth annual anniversary of the Vesting Commencement Date."}],"balance_after":59823,"derivative":{"exercise_price":4.77,"expiration_date":"2032-01-09","underlying":"Common Stock","underlying_shares":59823},"source":{"system":"sec-edgar","filing":"0001209191-22-002920","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1089409/000120919122002920/doc4.xml","form_type":"4"}},{"id":2592755,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":39423,"kind":"person","name":"DEPTULA-HICKS DARLENE M","position":1,"cik":"0001089409","reported_name":"DEPTULA-HICKS DARLENE M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Treasurer and CFO"}}],"security":"Common Stock","published_at":"2021-08-24T22:30:24.000Z","date":"2020-11-20","kind":"grant","acquired":true,"shares":26437,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This amendment to the Form 4 filed on November 24, 2020 is being filed solely to report the ownership of the restricted stock units (\"RSUs\") received by the Reporting Person in Table I of this Form 4 rather than in Table II as originally reported. No additional grants of securities are reported hereby."},{"field":"shares","element":"transactionShares","label":"F2","text":"The securities awarded are in the form of RSUs. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Twenty-five per cent (25%) of the total number of shares under the award shall vest on the first anniversary of the \"Vesting Commencement Date,\" July 1, 2020, and two and one twelfth per cent (2.083%) of the total number of shares under the award shall vest monthly thereafter, provided in each case that the Reporting Person remains a service provider of the Issuer continuously from the Vesting Commencement Date to the relevant date."}],"balance_after":26437,"source":{"system":"sec-edgar","filing":"0001209191-21-053227","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1089409/000120919121053227/doc4a.xml","form_type":"4/A","original_submission_date":"2020-11-24"}},{"id":2795307,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":39423,"kind":"person","name":"DEPTULA-HICKS DARLENE M","position":1,"cik":"0001089409","reported_name":"DEPTULA-HICKS DARLENE M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Treasurer and CFO"}}],"security":"Stock Option (right to buy)","published_at":"2021-03-11T21:06:50.000Z","date":"2021-03-09","kind":"grant","acquired":true,"shares":25894,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These options were granted under the Issuer's 2015 Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Twenty five percent (25%) of the total number of shares under the award shall vest on the first anniversary of the Vesting Commencement Date, March 9, 2021,  and thereafter in equal monthly installments over the remaining three years."}],"balance_after":54320,"derivative":{"exercise_price":7.24,"expiration_date":"2031-03-09","underlying":"Common Stock","underlying_shares":25894},"source":{"system":"sec-edgar","filing":"0001209191-21-019769","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1089409/000120919121019769/doc4.xml","form_type":"4"}},{"id":2886691,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":39423,"kind":"person","name":"DEPTULA-HICKS DARLENE M","position":1,"cik":"0001089409","reported_name":"DEPTULA-HICKS DARLENE M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Treasurer and CFO"}}],"security":"Common Stock","published_at":"2021-02-02T21:06:12.000Z","date":"2021-02-01","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The securities awarded are in the form of restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the\nIssuer's common stock. 25% of the shares shall vest on the one-year anniversary of the date of the grant, and thereafter shall vest in equal\nmonthly installments over the remaining three years."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"All share numbers reported are RSUs."}],"balance_after":56437,"source":{"system":"sec-edgar","filing":"0001209191-21-006720","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1089409/000120919121006720/doc4.xml","form_type":"4"}},{"id":2968612,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":39423,"kind":"person","name":"DEPTULA-HICKS DARLENE M","position":1,"cik":"0001089409","reported_name":"DEPTULA-HICKS DARLENE M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Treasurer and CFO"}}],"security":"Restricted Stock Units","published_at":"2020-11-25T00:04:40.000Z","date":"2020-11-20","kind":"grant","acquired":true,"shares":26437,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"shares","element":"transactionShares","label":"F1","text":"This option was issued in replacement of an option to purchase shares of F-star Therapeutics Limited."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Twenty-five per cent (25%) of the total number of Shares under Award shall vest on the first anniversary of the Vesting Commencement Date, July 1, 2020, and two and one twelfth per cent (2.083%) of the total number of Shares under Award shall vest monthly thereafter, provided in each case that the Participant remains a Service Provider continuously from the Vesting Commencement Date to the relevant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Twenty-five per cent (25%) of the total number of Shares under Award shall vest on the first anniversary of the Vesting Commencement Date, July 1, 2020, and two and one twelfth per cent (2.083%) of the total number of Shares under Award shall vest monthly thereafter, provided in each case that the Participant remains a Service Provider continuously from the Vesting Commencement Date to the relevant date."}],"balance_after":26437,"derivative":{"underlying":"Common Stock","underlying_shares":26437},"source":{"system":"sec-edgar","filing":"0001209191-20-060353","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1089409/000120919120060353/doc4.xml","form_type":"4"}},{"id":2968611,"issuer":{"id":115726,"kind":"organization","name":"F-star Therapeutics, Inc.","symbol":"FSTX"},"owners":[{"id":39423,"kind":"person","name":"DEPTULA-HICKS DARLENE M","position":1,"cik":"0001089409","reported_name":"DEPTULA-HICKS DARLENE M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Treasurer and CFO"}}],"security":"Stock Option (right to buy)","published_at":"2020-11-25T00:04:40.000Z","date":"2020-11-20","kind":"grant","acquired":true,"shares":28426,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This option was issued in replacement of an option to purchase shares of F-star Therapeutics Limited."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"28% of the options shall vest on the first anniversary of the commencement of employment of the option holder and 2% on the last day of each month subsequent to such first anniversary until the option is fully vested on the fourth anniversary from commencement of employment."}],"balance_after":28426,"derivative":{"exercise_price":16.62,"expiration_date":"2029-05-01","underlying":"Common Stock","underlying_shares":28426},"source":{"system":"sec-edgar","filing":"0001209191-20-060353","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1089409/000120919120060353/doc4.xml","form_type":"4"}},{"id":4281301,"issuer":{"id":8008,"kind":"organization","name":"Xenetic Biosciences, Inc."},"owners":[{"id":39423,"kind":"person","name":"DEPTULA-HICKS DARLENE M","position":1,"cik":"0001089409","reported_name":"DEPTULA-HICKS DARLENE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2017-06-15T20:57:29.000Z","date":"2016-12-20","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 20, 2016 the Issuer approved the issuance of a Stock Option Grant to the Reporting Owner under its 2014 Equity Incentive Plan (the \"Plan\"). The Reporting Owner has the right to purchase 40,000 shares of common stock of the Issuer under the Plan at an exercise price based on the closing price on December 19, 2016 of $3.50. The Option vests quarterly over twelve months."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On December 23, 2016 the Reporting Person filed a Form 4 that inadvertently reported that she beneficially owned an aggregate of 61,416 derivative securities. This amended Form 4 is being filed to correct the number of derivative securities owned by the Reporting Person following the reported transaction."}],"balance_after":40000,"derivative":{"exercise_price":3.5,"exercise_date":"2017-12-20","expiration_date":"2026-12-20","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001662252-17-000119","document":"form4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1089409/000166225217000119/form4a.xml","form_type":"4/A","original_submission_date":"2016-12-23"}},{"id":4281300,"issuer":{"id":8008,"kind":"organization","name":"Xenetic Biosciences, Inc."},"owners":[{"id":39423,"kind":"person","name":"DEPTULA-HICKS DARLENE M","position":1,"cik":"0001089409","reported_name":"DEPTULA-HICKS DARLENE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2017-06-15T20:57:29.000Z","date":"2016-12-20","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 20, 2016 the Issuer approved the issuance of a Stock Option Grant to the Reporting Owner under its 2014 Equity Incentive Plan (the \"Plan\"). The Reporting Owner has the right to purchase 40,000 shares of common stock of the Issuer under the Plan at an exercise price based on the closing price on December 19, 2016 of $3.50. The Option vests quarterly over twelve months."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On December 23, 2016 the Reporting Person filed a Form 4 that inadvertently reported that she beneficially owned an aggregate of 61,416 derivative securities. This amended Form 4 is being filed to correct the number of derivative securities owned by the Reporting Person following the reported transaction."}],"balance_after":30000,"derivative":{"exercise_price":3.5,"exercise_date":"2017-09-20","expiration_date":"2026-12-20","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001662252-17-000119","document":"form4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1089409/000166225217000119/form4a.xml","form_type":"4/A","original_submission_date":"2016-12-23"}},{"id":4281299,"issuer":{"id":8008,"kind":"organization","name":"Xenetic Biosciences, Inc."},"owners":[{"id":39423,"kind":"person","name":"DEPTULA-HICKS DARLENE M","position":1,"cik":"0001089409","reported_name":"DEPTULA-HICKS DARLENE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2017-06-15T20:57:29.000Z","date":"2016-12-20","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 20, 2016 the Issuer approved the issuance of a Stock Option Grant to the Reporting Owner under its 2014 Equity Incentive Plan (the \"Plan\"). The Reporting Owner has the right to purchase 40,000 shares of common stock of the Issuer under the Plan at an exercise price based on the closing price on December 19, 2016 of $3.50. The Option vests quarterly over twelve months."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On December 23, 2016 the Reporting Person filed a Form 4 that inadvertently reported that she beneficially owned an aggregate of 61,416 derivative securities. This amended Form 4 is being filed to correct the number of derivative securities owned by the Reporting Person following the reported transaction."}],"balance_after":20000,"derivative":{"exercise_price":3.5,"exercise_date":"2017-06-20","expiration_date":"2026-12-20","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001662252-17-000119","document":"form4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1089409/000166225217000119/form4a.xml","form_type":"4/A","original_submission_date":"2016-12-23"}},{"id":4281298,"issuer":{"id":8008,"kind":"organization","name":"Xenetic Biosciences, Inc."},"owners":[{"id":39423,"kind":"person","name":"DEPTULA-HICKS DARLENE M","position":1,"cik":"0001089409","reported_name":"DEPTULA-HICKS DARLENE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2017-06-15T20:57:29.000Z","date":"2016-12-20","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 20, 2016 the Issuer approved the issuance of a Stock Option Grant to the Reporting Owner under its 2014 Equity Incentive Plan (the \"Plan\"). The Reporting Owner has the right to purchase 40,000 shares of common stock of the Issuer under the Plan at an exercise price based on the closing price on December 19, 2016 of $3.50. The Option vests quarterly over twelve months."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On December 23, 2016 the Reporting Person filed a Form 4 that inadvertently reported that she beneficially owned an aggregate of 61,416 derivative securities. This amended Form 4 is being filed to correct the number of derivative securities owned by the Reporting Person following the reported transaction."}],"balance_after":10000,"derivative":{"exercise_price":3.5,"exercise_date":"2017-03-20","expiration_date":"2026-12-20","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001662252-17-000119","document":"form4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1089409/000166225217000119/form4a.xml","form_type":"4/A","original_submission_date":"2016-12-23"}},{"id":4288736,"issuer":{"id":11728,"kind":"organization","name":"T2 Biosystems, Inc.","symbol":"TTOO"},"owners":[{"id":39423,"kind":"person","name":"DEPTULA-HICKS DARLENE M","position":1,"cik":"0001089409","reported_name":"DEPTULA-HICKS DARLENE M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-06-08T20:15:00.000Z","date":"2017-06-06","kind":"purchase","acquired":true,"shares":4000,"price":3.58,"value":14320.0,"ownership":{"direct":true},"balance_after":4000,"source":{"system":"sec-edgar","filing":"0001104659-17-038149","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1089409/000110465917038149/a4.xml","form_type":"4"}},{"id":4338590,"issuer":{"id":11728,"kind":"organization","name":"T2 Biosystems, Inc.","symbol":"TTOO"},"owners":[{"id":39423,"kind":"person","name":"DEPTULA-HICKS DARLENE M","position":1,"cik":"0001089409","reported_name":"DEPTULA-HICKS DARLENE M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-05-02T19:54:39.000Z","date":"2016-05-01","kind":"grant","acquired":true,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the total shares vest on 05/01/2018, and the remaining shares vest in substantially equal monthly installments over the following 36 months, to be fully vested on 05/01/2021."}],"balance_after":175000,"derivative":{"exercise_price":4.74,"expiration_date":"2027-05-01","underlying":"Common Stock","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0001104659-17-028860","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1089409/000110465917028860/a4.xml","form_type":"4"}},{"id":4512681,"issuer":{"id":8008,"kind":"organization","name":"Xenetic Biosciences, Inc."},"owners":[{"id":39423,"kind":"person","name":"DEPTULA-HICKS DARLENE M","position":1,"cik":"0001089409","reported_name":"DEPTULA-HICKS DARLENE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2016-12-23T18:58:51.000Z","date":"2016-12-20","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 20, 2016 the Issuer approved the issuance of a Stock Option Grant to the Reporting Owner under its 2014 Equity Incentive Plan (the \"Plan\"). The Reporting Owner has the right to purchase 40,000 shares of common stock of the Issuer under the Plan at an exercise price based on the closing price on December 19, 2016 of $3.50. The Option vests quarterly over twelve months."}],"balance_after":61416,"derivative":{"exercise_price":3.5,"exercise_date":"2017-12-20","expiration_date":"2026-12-20","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001662252-16-000299","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1089409/000166225216000299/form4.xml","form_type":"4"}},{"id":4512680,"issuer":{"id":8008,"kind":"organization","name":"Xenetic Biosciences, Inc."},"owners":[{"id":39423,"kind":"person","name":"DEPTULA-HICKS DARLENE M","position":1,"cik":"0001089409","reported_name":"DEPTULA-HICKS DARLENE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2016-12-23T18:58:51.000Z","date":"2016-12-20","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 20, 2016 the Issuer approved the issuance of a Stock Option Grant to the Reporting Owner under its 2014 Equity Incentive Plan (the \"Plan\"). The Reporting Owner has the right to purchase 40,000 shares of common stock of the Issuer under the Plan at an exercise price based on the closing price on December 19, 2016 of $3.50. The Option vests quarterly over twelve months."}],"balance_after":51416,"derivative":{"exercise_price":3.5,"exercise_date":"2017-09-20","expiration_date":"2026-12-20","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001662252-16-000299","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1089409/000166225216000299/form4.xml","form_type":"4"}},{"id":4512679,"issuer":{"id":8008,"kind":"organization","name":"Xenetic Biosciences, Inc."},"owners":[{"id":39423,"kind":"person","name":"DEPTULA-HICKS DARLENE M","position":1,"cik":"0001089409","reported_name":"DEPTULA-HICKS DARLENE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2016-12-23T18:58:51.000Z","date":"2016-12-20","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 20, 2016 the Issuer approved the issuance of a Stock Option Grant to the Reporting Owner under its 2014 Equity Incentive Plan (the \"Plan\"). The Reporting Owner has the right to purchase 40,000 shares of common stock of the Issuer under the Plan at an exercise price based on the closing price on December 19, 2016 of $3.50. The Option vests quarterly over twelve months."}],"balance_after":41416,"derivative":{"exercise_price":3.5,"exercise_date":"2017-06-20","expiration_date":"2026-12-20","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001662252-16-000299","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1089409/000166225216000299/form4.xml","form_type":"4"}},{"id":4512678,"issuer":{"id":8008,"kind":"organization","name":"Xenetic Biosciences, Inc."},"owners":[{"id":39423,"kind":"person","name":"DEPTULA-HICKS DARLENE M","position":1,"cik":"0001089409","reported_name":"DEPTULA-HICKS DARLENE M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2016-12-23T18:58:51.000Z","date":"2016-12-20","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 20, 2016 the Issuer approved the issuance of a Stock Option Grant to the Reporting Owner under its 2014 Equity Incentive Plan (the \"Plan\"). The Reporting Owner has the right to purchase 40,000 shares of common stock of the Issuer under the Plan at an exercise price based on the closing price on December 19, 2016 of $3.50. The Option vests quarterly over twelve months."}],"balance_after":31416,"derivative":{"exercise_price":3.5,"exercise_date":"2017-03-20","expiration_date":"2026-12-20","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001662252-16-000299","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1089409/000166225216000299/form4.xml","form_type":"4"}}]}